zurück

Finerenone (chronic kidney disease associated with type 2 diabetes; stage 3 and 4 with albuminuria)

 

Subject:

  • Active Substance: Finerenone
  • Name: Kerendia®
  • Therapeutic area: Chronic kidney disease
  • Pharmaceutical company: Bayer Vital GmbH

 

Time table:

  • Start: 01.03.2023
  • Publication of assessment: 01.06.2023
  • End of public hearing: 22.06.2023
  • Final decision by G-BA: mddle of August 2023

 

Comparative therapy:

  • An optimized standard of care for the treatment of chronic kidney disease and type 2 diabetes taking into account the underlying disease(s) and common comorbidities (such as dyslipoproteinemia, hypertension, anemia)